If you're frustrated with the challenges of outsourcing critical evidence synthesis work — like limited control, lack of flexibility, long timelines, and increasing costs — we understand your concerns. While outsourcing can provide necessary expertise, we believe there's a better way to manage the process, giving you more control without completely removing the value that vendors bring. Our solution is designed to help you strike the right balance.
Pharmaceutical companies, especially HTA departments, often face significant challenges when outsourcing evidence synthesis:
Our solution addresses these pain points while still allowing you to leverage vendor expertise where necessary. With increased control, flexibility, and opportunities for learning, you’ll be empowered to make the most of your evidence synthesis efforts—without completely eliminating the need for vendors.
If you're frustrated by the limitations of outsourcing critical evidence synthesis — such as limited control, lack of flexibility, long timelines, and escalating costs — we offer a transformative alternative. Our solution combines cutting-edge software with expert consultancy to give you control over the entire evidence synthesis process while maintaining access to high-level vendor expertise where needed.
We provide a web-based application, designed specifically for conducting Network Meta-Analysis (NMA) and Indirect Treatment Comparisons (ITC). This software, combined with our consultancy expertise, empowers your team to conduct evidence synthesis in-house, offering enhanced control, flexibility, and cost efficiency.
Our solution offers a game-changing alternative to the typical challenges of outsourcing evidence synthesis. By partnering with us, you gain key advantages that enhance your control, flexibility, and efficiency, through a seamless combination of advanced software tools and expert consultancy.
Our solution is packed with features designed to simplify your evidence synthesis journey:
Recomended events for you
15
Feb
The Effective Statistician Conference 2024,
15
Oct
Evidera Ltd., London, United Kingdom
28
Mar
European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium
22
Nov
European Statistical Meeting on Evidence Synthesis, Brussels, Belgium
27
Oct
24th Cochrane Colloquium, Seoul, South Korea
15
Sep
IMI GetReal, London, United Kingdom
22
Aug
37th Annual Conference of the International Society for Clinical Biostatistics (ISCB), Birmingham, United Kingdom
23
May
PSI Conference 2016 - Promoting Statistical Insight and Collaboration in Drug Development, Berlin, Germany
12
Nov
Amgen, Milan, Italy
05
Oct
23rd Cochrane Colloquium, Vienna, Austria
15
Oct
36th Annual Conference of the International Society for Clinical Biostatistics (ISCB), Utrecht, Netherlands
15
Oct
Royal Statistical Society, London, United Kingdom
15
Oct
Biogen, Cambridge, United States
Thomas initially joined us as an methodological expert in treatment comparisons, but quickly became an integral part of our team. His expertise and commitment were instrumental in delivering high-quality outcomes on time, and his collaborative approach ensured universal satisfaction. Principal Biostatistician, Drug Sponsor
Thomas never missed a detail and was always open to feedback, demonstrating a level of completeness and thoroughness that is rare. His ability to accommodate different perspectives while maintaining the highest standards of quality made him one of the best biostatisticians I have ever worked with. Senior HEOR & RWE Manager, Drug Sponsor
I particularly enjoyed Thomas’s innovative approach and the fresh ideas he consistently brought to the table. He had a unique ability to challenge the status quo, always pushing for better solutions and deeper insights. His skills in statistics and applied statistical models are top-notch, and his ability to contextualize these models within the broader scope of clinical trials was exceptional. Senior HEOR & RWE Manager, Drug Sponsor
One of Thomas's standout qualities is his ability to understand and communicate complex statistical and medical concepts clearly. His ability to summarise results for the dossier team during appraisal meetings was particularly noteworthy, and stakeholders consistently praised his work. Lead Biostatistician, Drug Sponsor